PCSK9 and breast cancer survival: a Mendelian Randomization study
Potential reasons for the discrepant results are different genetic models, sample selection criteria, and the time-variability of HR estimates. They should be explored before considering PCSK9 a therapeutic target in BC patients.
Authors
- Amy M. Mason (ORCID: https://orcid.org/0000-0002-8019-0777)
- Stephen Burgess (ORCID: https://orcid.org/0000-0001-5365-8760)
- Ville Salo (ORCID: https://orcid.org/0009-0009-0102-7102)
- Johannes Kettunen
- Janne Pott
Institutions
- University of Cambridge (GB)
- Cambridge School (PT)
- Bridge University (SS)
- MRC Biostatistics Unit (GB)
- Oulu University of Applied Sciences (FI)
- University of Oulu (FI)
Publication Details
- Journal
- Cancer Epidemiology Biomarkers & Prevention
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1158/1055-9965.epi-25-1569
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00